This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ceresoli, G. L. Articles by Santoro, A. Search for Related Content PubMed PubMed Citation Articles by Ceresoli, G. L. Articles by Santoro, A. Social Bookmarking                            What's this?

Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [¹⁸F]Fluorodeoxyglucose

Giovanni L. Ceresoli, Arturo Chiti, Paolo A. Zucali, Marcello Rodari, Romano F. Lutman, Silvia Salamina, Matteo Incarbone, Marco Alloisio, Armando Santoro

From the Departments of Medical Oncology and Hematology, Nuclear Medicine, Radiology, and Thoracic Surgery, Istituto Clinico Humanitas IRCCS (Isituto di Ricovero e Cura a Carattere Scientifico), Rozzano, Milan, Italy

Address reprint requests to Giovanni L. Ceresoli, MD, Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy; e-mail: giovanni_luca.ceresoli{at}humanitas.it

PURPOSE: Response evaluation with conventional criteria based on computed tomography (CT) is particularly challenging in malignant pleural mesothelioma (MPM) due to its diffuse pattern of growth. There is growing evidence that therapy-induced changes in tumor [¹⁸F]fluorodeoxyglucose (FDG) uptake as measured by positron emission tomography (PET) may predict response and patient outcome early in the course of treatment.

PATIENTS AND METHODS: Patients with histologically proven MPM, not candidates to curative surgery, scheduled to undergo palliative chemotherapy with a pemetrexed-based regimen were eligible for this study. Patients were evaluated by FDG-PET and CT at baseline and after two cycles of therapy. A decrease of 25% or more in tumor FDG uptake as measured by standardized uptake value was defined as a metabolic response (MR). Best overall response from CT scans was determined according to previously published criteria.

RESULTS: Twenty-two patients were included in the study, and 20 were assessable for early metabolic response with FDG-PET. Of these, eight were classified as responders (40%) and 12 as nonresponders (60%). Early MR was significantly correlated to median time-to-tumor progression (TTP) with a median TTP for metabolic responders of 14 months versus 7 months for nonresponders (P = .02). No correlation was found between TTP and radiologic response evaluated by CT. Patients with a MR had a trend toward longer overall survival.

CONCLUSION: The use of MR evaluated by FDG-PET in the assessment of treatment efficacy in MPM appears promising. Our observations need to be validated in a larger prospective series.

Presented in part at the 11th World Conference on Lung Cancer in Barcelona, Spain, July 3-6, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]

				M. R. Benz, J. Czernin, M. S. Allen-Auerbach, W. D. Tap, S. M. Dry, D. Elashoff, K. Chow, V. Evilevitch, J. J. Eckardt, M. E. Phelps, et al. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas Clin. Cancer Res., April 15, 2009; 15(8): 2856 - 2863. [Abstract] [Full Text] [PDF]

				M. Allen-Auerbach and W. A. Weber Measuring Response with FDG-PET: Methodological Aspects Oncologist, April 1, 2009; 14(4): 369 - 377. [Abstract] [Full Text] [PDF]

				D. Breen, A. Fraticelli, L. Greillier, S. Mallawathantri, and P. Astoul Redo medical thoracoscopy is feasible in patients with pleural diseases - a series Interactive CardioVascular and Thoracic Surgery, March 1, 2009; 8(3): 330 - 333. [Abstract] [Full Text] [PDF]

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, A. Chiti, and A. Santoro 11C-Labeled Methionine and Evaluation of Malignant Pleural Mesothelioma N. Engl. J. Med., November 8, 2007; 357(19): 1982 - 1984. [Full Text] [PDF]

				R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458. [Abstract] [Full Text] [PDF]

				D. H. Sterman, A. Recio, R. G. Carroll, C. T. Gillespie, A. Haas, A. Vachani, V. Kapoor, J. Sun, R. Hodinka, J. L. Brown, et al. A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses Clin. Cancer Res., August 1, 2007; 13(15): 4456 - 4466. [Abstract] [Full Text] [PDF]

				D. A. Torigian, S. S. Huang, M. Houseni, and A. Alavi Functional Imaging of Cancer with Emphasis on Molecular Techniques CA Cancer J Clin, July 1, 2007; 57(4): 206 - 224. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]